Assessing the clinical effectiveness of an algorithmic approach for mucosal lichen planus (MLP): A retrospective review - 15/05/16
Abstract |
Background |
Mucosal lichen planus (MLP) is a therapeutic challenge in need of a new treatment approach because of its debilitating effect on patient's quality of life.
Objective |
We sought to evaluate a standardized treatment plan for patients with MLP. A second objective was to describe the effect of mycophenolate mofetil in this patient population.
Methods |
The study retrospectively analyzed 53 patients with MLP treated using a standardized algorithm. The number of MLP lesions, disease activity, and pain at the last visit were compared with baseline scores determined at the initial visit. Results were analyzed using the paired samples t test and confirmed with the Wilcoxon matched pairs signed rank test.
Results |
The average number of lesions was reduced from 3.77 to 1.67 (P < .001). The average disease activity was reduced from 2.73 to 0.90 (P < .001). Average pain reported decreased from 2.03 to 1.03 (P < .001).
Limitations |
This study was a retrospective analysis of a small patient population. There was no universal symptom severity scale used at the time of treatment for some patients.
Conclusion |
The standardized treatment plan reduced symptoms for patients with MLP. Mycophenolate mofetil appears to be a reasonable treatment option for these patients.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune disorder, mucosal lichen planus, mycophenolate mofetil, oral lichen planus, treatment algorithm, vaginal lichen planus
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 74 - N° 6
P. 1073 - juin 2016 Retour au numéro
Article précédent
- ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice
- Eva Vilarrasa, Jaume Notario, Xavier Bordas, Anna López-Ferrer, Ignasi J. Gich, Lluís Puig
- Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial
- Gaël Deplanque, Radj Gervais, Alain Vergnenegre, Lionel Falchero, Pierre-Jean Souquet, Jean-Michel Chavaillon, Bruno Taviot, Ghislaine Fraboulet, Hakim Saal, Caroline Robert, Olivier Chosidow, CYTAR investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?